Product category:
Chemical analysis equipment
News Release from: Procognia
Edited by the Laboratorytalk Editorial
Team on 16 November 2006
Commercialising functional human protein
arrays
In November 2004, Sigma-Aldrich and Procognia announced an exclusive partnership for commercialisation of functional human protein arrays
Sigma-Aldrich and Procognia have an exclusive agreement that calls for Sigma-Aldrich to market novel arrays of functional human proteins developed by Procognia This agreement will significantly expand Sigma-Aldrich's pipeline of products for the advancement of proteomic research
This article was originally published on Laboratorytalk on 23 Jan 2002 at 8.00am (UK)
Related stories
Functional proteins for cancer research
Sense Proteomic has announced that Expressarray p53, its first functional protein array product to aid in cancer research, is now available to researchers
First commercial array of functional proteins
Collection of functional potassium channel regulatory proteins, immobilised in microtitre plate format, is said to be the first functional protein array to be made commercially available
Procognia has developed proprietary tag technology to create the first arrays of biologically-related human proteins that retain their native functions in the array format.
The first protein array in the pipeline of products will contain wild type human p53 and its important germline SNP variants.
The p53 protein is implicated in most cancers when its normal function to suppress tumor growth is reduced or lost through variation in its sequence.
Further reading
Agreement targets field of protein glycoanalysis
The combination of Qiagen's Qproteome products with Procognia's on-chip glycoanalysis technology creates guided fractionation solutions
First drug screening human kinase protein array
Procognia announced the introduction of the first human kinase protein function array for use in compound profiling and other drug screening applications in September 2005
U-c fingerprint for rapid glycoanalysis
Procognia's U-c fingerprint technology provides a quantitative analysis of the glycans in a protein sample without protein purification or cleavage at the Centre for Bioanalytical Sciences, Ireland
Procognia's functionally arrayed SNP variant proteins will be the first tool that enables researchers to investigate the mechanism of cancer progression on many proteins in parallel.
Additional protein arrays to be launched in the coming months will contain selected sets of biologically related human proteins including collections of proteins associated with key diseases including cancer and signal transduction.
These arrays will enable understanding of biological pathways and the rapid screening of inhibitors of specific proteins in those pathways.
These products are expected to become broadly used tools by most pharmaceutical and biotechnology companies to increase the speed and output of their drug discovery programmes.
Other terms of the exclusive relationship between Sigma-Aldrich and Procognia were not released.
In addition, Procognia has raised new financing totaling $23.5 million.
Participants to support its development efforts included lead investor Apax Partners Funds, as well as other existing investors Evergreen Partners and Koor CVC, and new investor Star Ventures.
David Harvey, Chairman and CEO of Sigma-Aldrich, remarked, "I am pleased that Sigma-Aldrich will have the opportunity to exclusively market a product with the power to finally deliver functional arrays of human proteins.
"This proprietary technology represents a significant advancement over existing protein array technologies, which do not orient nor confer functionality of proteins on the array.
"This leading achievement will dramatically advance proteomic research to further uncover the mechanisms of human disease by enabling researchers to conduct functional assays of large numbers of proteins in a parallel manner.
"We feel that the technology developed by Procognia is the most innovative protein array technology available and the only technology that allows true functional analysis of proteins in parallel".
Ron Long, Procognia's CEO and former CEO of Amersham Pharmacia Biotech, said, "Sigma-Aldrich is emerging as the strongest force in leading edge proteomic tools for the life sciences market today, and I feel that they are the best partner for Procognia's protein function arrays.
"With the human p53 SNP arrays, we will mark a first in functional protein array development and open the door for rapid uptake of the future protein array products that will follow.".
• Procognia: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
